← Back to Search

Small Molecule Inhibitor

A Phase II Trial Evaluating WNT974 in Patients With Metastatic Head and Neck Squamous Cell Carcinoma

Ann Arbor, MI
Phase 2
Waitlist Available
Led By Francis Worden, M.D.
Research Sponsored by University of Michigan Rogel Cancer Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 6 months post treatment
Awards & highlights
No Placebo-Only Group

Summary

Given that up-regulation of the Wnt pathway has been identified as having a significant role in carcinogenesis in advanced head and neck squamous cell carcinoma, the investigator believes that inhibition of Porcupine via WNT974 will result in tumor control hence improvement in disease free and overall survival in these patients with a tolerable toxicity profile. As suggested by pre-clinical models, patients with a tumor harboring a Notch receptor (any of the four) loss of function mutation may have a greater response rate to treatment with WNT974. The investigator aims to address this question by administration of single agent WNT974 and following response radiologically along with close clinical follow up to monitor toxicities.

See full description
Eligible Conditions
  • Head and Neck Squamous Cell Carcinoma

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~6 months post treatment
This trial's timeline: 3 weeks for screening, Varies for treatment, and 6 months post treatment for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
The number of patients with stable disease, complete response and partial response
Secondary study objectives
Duration of time from start of treatment to time of progression
Number of patients that respond to treatment
The number of patients alive at 6 months post treatment
+1 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: WNT974Experimental Treatment1 Intervention
Patients will receive 10 mg of WNT974 daily by mouth.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
WNT974
2014
Completed Phase 2
~20

Find a Location

Closest Location:University of Michigan Comprehensive Cancer Center· Ann Arbor, MI

Who is running the clinical trial?

University of Michigan Rogel Cancer CenterLead Sponsor
301 Previous Clinical Trials
20,881 Total Patients Enrolled
Francis Worden, M.D.Principal InvestigatorUniversity of Michigan Rogel Cancer Center
4 Previous Clinical Trials
43 Total Patients Enrolled
~0 spots leftby Feb 2026